Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 20

Results For "commercialization"

336 News Found

China medical devices market to surpass $42 billion in 2022: GlobalData
News | July 10, 2022

China medical devices market to surpass $42 billion in 2022: GlobalData

Domestic devices are usually preferred over imported medical devices in the national or regional procurement.


WuXi STA opens Oligonucleotide and Peptide manufacturing facility
News | July 08, 2022

WuXi STA opens Oligonucleotide and Peptide manufacturing facility

Site Enhances New Modality CRDMO Platform Capacity for Customers


Regeneron completes purchase of Sanofi's stake in Libtayo
News | July 06, 2022

Regeneron completes purchase of Sanofi's stake in Libtayo

Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions


Ardelyx gets into $20 million financing agreement with HealthCare Royalty Partners
News | July 02, 2022

Ardelyx gets into $20 million financing agreement with HealthCare Royalty Partners

HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States


Akebia Therapeutics regaining rights to Vadadustat in the US, Europe and China
News | July 01, 2022

Akebia Therapeutics regaining rights to Vadadustat in the US, Europe and China

Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia


ANI Pharmaceuticals gets FDA approval of Clorazepate Dipotassium Tablets USP
Drug Approval | June 24, 2022

ANI Pharmaceuticals gets FDA approval of Clorazepate Dipotassium Tablets USP

ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.


Biolexis and Akston Biosciences announce encouraging results of thermostable 2nd Gen COVID-19 vaccine
News | June 24, 2022

Biolexis and Akston Biosciences announce encouraging results of thermostable 2nd Gen COVID-19 vaccine

An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.


Menarini Group and Radius Health submit new drug application to the USFDA for Elacestrant
Drug Approval | June 23, 2022

Menarini Group and Radius Health submit new drug application to the USFDA for Elacestrant

Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients


Merck appoints Chirfi Guindo as CMO for Merck Human Health
People | June 22, 2022

Merck appoints Chirfi Guindo as CMO for Merck Human Health

Guindo will be responsible for leading the development and implementation of the company’s long-term strategy for the Human Health portfolio.


Stelis Biopharma’s two biologics manufacturing facilities receive EU cGMP accreditation
News | June 18, 2022

Stelis Biopharma’s two biologics manufacturing facilities receive EU cGMP accreditation

Both manufacturing facilities are based out of Benguluru, India